Research programme: checkpoint kinase 1 inhibitors - Cascadian/Sentinel

Drug Profile

Research programme: checkpoint kinase 1 inhibitors - Cascadian/Sentinel

Alternative Names: CASC-578; S024; S070; S081; S091; S158; S209

Latest Information Update: 24 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sentinel Oncology
  • Developer Cascadian Therapeutics; Sentinel Oncology
  • Class Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; DNA repair inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Apr 2018 Preclinical development of CASC 578 for Cancer is ongoing in United Kingdom and USA (PO)
  • 28 Mar 2018 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
  • 09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top